Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2023

Open Access 01-12-2023 | Metastasis | Research

TAP1, a potential immune-related prognosis biomarker with functional significance in uveal melanoma

Authors: Ru Zhu, Yu-Ting Chen, Bo-Wen Wang, Ya-Yan You, Xing-Hua Wang, Hua-Tao Xie, Fa-Gang Jiang, Ming-Chang Zhang

Published in: BMC Cancer | Issue 1/2023

Login to get access

Abstract

Background

TAP1 is an immunomodulation-related protein that plays different roles in various malignancies. This study investigated the transcriptional expression profile of TAP1 in uveal melanoma (UVM), revealed its potential biological interaction network, and determined its prognostic value.

Methods

CIBERSORT and ESTIMATE bioinformatic methods were used on data sourced from The Cancer Genome Atlas database (TCGA) to determine the correlation between TAP1 expression, UVM prognosis, biological characteristics, and immune infiltration. Gene set enrichment analysis (GSEA) was used to discover the signaling pathways associated with TAP1, while STRING database and CytoHubba were used to construct protein–protein interaction (PPI) and competing endogenous RNA (ceRNA) networks, respectively. An overall survival (OS) prognostic model was constructed to test the predictive efficacy of TAP1, and its effect on the in vitro proliferation activity and metastatic potential of UVM cell line C918 cells was verified by RNA interference.

Results

There was a clear association between TAP1 expression and UVM patient prognosis. Upregulated TAP1 was strongly associated with a shorter survival time, higher likelihood of metastasis, and higher mortality outcomes. According to GSEA analysis, various immunity-related signaling pathways such as primary immunodeficiency were enriched in the presence of elevated TAP1 expression. A PPI network and a ceRNA network were constructed to show the interactions among mRNAs, miRNAs, and lncRNAs. Furthermore, TAP1 expression showed a significant positive correlation with immunoscore, stromal score, CD8+ T cells, and dendritic cells, whereas the correlation with B cells and neutrophils was negative. The Cox regression model and calibration plots confirmed a strong agreement between the estimated OS and actual observed patient values. In vitro silencing of TAP1 expression in C918 cells significantly inhibited cell proliferation and metastasis.

Conclusions

This study is the first to demonstrate that TAP1 expression is positively correlated with clinicopathological factors and poor prognosis in UVM. In vitro experiments also verified that TAP1 is associated with C918 cell proliferation, apoptosis, and metastasis. These results suggest that TAP1 may function as an oncogene, prognostic marker, and importantly, as a novel therapeutic target in patients with UVM.
Appendix
Available only for authorised users
Literature
1.
2.
Jager MJ, Shields CL, Cebulla CM, Abdel-Rahman MH, Grossniklaus HE, Stern MH, et al. Uveal melanoma. Nat Rev Dis Primers. 2020;6(1):24.CrossRefPubMed
3.
Fu Y, Xiao W. Recent Advances and Challenges in Uveal Melanoma Immunotherapy. Cancers (Basel). 2022;14(13):3094.CrossRefPubMed
4.
Levidou G, Gajdzis P, Cassoux N, Donizy P, Masaoutis C, Gajdzis M, et al. Histone deacetylase (HDAC)-1, −2, −4, and −6 in uveal melanomas: associations with Clinicopathological parameters and Patients' survival. Cancers. 2021;13(19):4763.CrossRefPubMedPubMedCentral
5.
Kashyap S, Jha J, Singh MK, Singh L, Sen S, Kaur J, et al. DNA damage response proteins and its role in tumor progression of uveal melanoma with patient outcome. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 2020;22(9):1472–80.CrossRef
6.
Singh MK, Singh L, Pushker N, Saini N, Meel R, Chosdol K, et al. Identification of canonical NFκB (C-NFκB) pathway in uveal melanoma and their relation with patient outcome. Clin Exp Metastasis. 2019;36(3):271–90.CrossRefPubMed
7.
Gallenga CE, Franco E, Adamo GG, Violanti SS, Tassinari P, Tognon M, et al. Genetic basis and molecular mechanisms of uveal melanoma metastasis: a focus on prognosis. Front Oncol. 2022;12:828112.CrossRefPubMedPubMedCentral
8.
9.
Leone P, Shin EC, Perosa F, Vacca A, Dammacco F, Racanelli V. MHC class I antigen processing and presenting machinery: organization, function, and defects in tumor cells. J Natl Cancer Inst. 2013;105(16):1172–87.CrossRefPubMed
10.
Meng J, Li W, Zhang M, Hao Z, Fan S, Zhang L, et al. An update meta-analysis and systematic review of TAP polymorphisms as potential biomarkers for judging cancer risk. Pathol Res Pract. 2018;214(10):1556–63.CrossRefPubMed
11.
Tabassum A, Samdani MN, Dhali TC, Alam R, Ahammad F, Samad A, et al. Transporter associated with antigen processing 1 (TAP1) expression and prognostic analysis in breast, lung, liver, and ovarian cancer. J Mol Med (Berl). 2021;99(9):1293–309.CrossRefPubMed
12.
Li X, Zeng S, Ding Y, Nie Y, Yang M. Comprehensive analysis of the potential immune-related biomarker transporter associated with antigen processing 1 that inhibits metastasis and invasion of ovarian Cancer cells. Front Mol Biosci. 2021;8:763958.CrossRefPubMedPubMedCentral
13.
Wang Y, Yan K, Lin J, Liu Y, Wang J, Li X, et al. CD8+ T cell co-expressed genes correlate with clinical phenotype and microenvironments of urothelial Cancer. Front Oncol. 2020;10:553399.CrossRefPubMedPubMedCentral
14.
Zhang X, Sabio E, Krishna C, Ma X, Wang J, Jiang H, et al. Qa-1(b) Modulates Resistance to Anti-PD-1 Immune Checkpoint Blockade in Tumors with Defects in Antigen Processing. Mol Cancer Res. 2021;19(6):1076–84.CrossRefPubMedPubMedCentral
15.
Laurent C, Valet F, Planque N, Silveri L, Maacha S, Anezo O, et al. High PTP4A3 phosphatase expression correlates with metastatic risk in uveal melanoma patients. Cancer Res. 2011;71(3):666–74.CrossRefPubMed
16.
van Essen TH, van Pelt SI, Bronkhorst IH, Versluis M, Némati F, Laurent C, et al. Upregulation of HLA expression in primary uveal melanoma by infiltrating leukocytes. PLoS One. 2016;11(10):e0164292.CrossRefPubMedPubMedCentral
17.
Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47.CrossRefPubMedPubMedCentral
18.
19.
Kanehisa M, Sato Y, Furumichi M, Morishima K, Tanabe M. New approach for understanding genome variations in KEGG. Nucleic Acids Res. 2019;47(D1):D590–d595.CrossRefPubMed
20.
Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. Omics : a journal of integrative biology. 2012;16(5):284–7.CrossRefPubMed
21.
Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545–50.CrossRefPubMedPubMedCentral
22.
Li T, Fan J, Wang B, Traugh N, Chen Q, Liu JS, et al. TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res. 2017;77(21):e108–10.CrossRefPubMedPubMedCentral
23.
Yoshihara K, Shahmoradgoli M, Martínez E, Vegesna R, Kim H, Torres-Garcia W, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013;4:2612.CrossRefPubMed
24.
Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13(11):2498–504.CrossRefPubMedPubMedCentral
25.
Chin CH, Chen SH, Wu HH, Ho CW, Ko MT. Lin CY: cytoHubba: identifying hub objects and sub-networks from complex interactome. BMC Syst Biol. 2014;8(4):1–7.
26.
Liu J, Lichtenberg T, Hoadley KA, Poisson LM, Lazar AJ, Cherniack AD, et al. An integrated TCGA Pan-Cancer clinical data resource to drive high-quality survival outcome analytics. Cell. 2018;173(2):400–416.e411.CrossRefPubMedPubMedCentral
27.
Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez JC, et al. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC bioinformatics. 2011;12:77.CrossRefPubMedPubMedCentral
28.
29.
30.
Ling A, Löfgren-Burström A, Larsson P, Li X, Wikberg ML, Öberg Å, et al. TAP1 down-regulation elicits immune escape and poor prognosis in colorectal cancer. Oncoimmunology. 2017;6(11):e1356143.CrossRefPubMedPubMedCentral
31.
Reschke R, Gajewski TF. CXCL9 and CXCL10 bring the heat to tumors. Sci Immunol. 2022;7(73):eabq6509.CrossRefPubMed
32.
Halama N, Zoernig I, Berthel A, Kahlert C, Klupp F, Suarez-Carmona M, et al. Tumoral immune cell exploitation in colorectal Cancer metastases can be targeted effectively by anti-CCR5 therapy in Cancer patients. Cancer Cell. 2016;29(4):587–601.CrossRefPubMed
33.
Fisch D, Bando H, Clough B, Hornung V, Yamamoto M, Shenoy AR, et al. Human GBP1 is a microbe-specific gatekeeper of macrophage apoptosis and pyroptosis. EMBO J. 2019;38(13):e100926.CrossRefPubMedPubMedCentral
34.
35.
Gupta R, Forloni M, Bisserier M, Dogra SK, Yang Q, Wajapeyee N. Interferon alpha-inducible protein 6 regulates NRASQ61K-induced melanomagenesis and growth. Elife. 2016;5:e16432.CrossRefPubMedPubMedCentral
36.
Puig-Butille JA, Escámez MJ, Garcia-Garcia F, Tell-Marti G, Fabra À, Martínez-Santamaría L, et al. Capturing the biological impact of CDKN2A and MC1R genes as an early predisposing event in melanoma and non melanoma skin cancer. Oncotarget. 2014;5(6):1439–51.CrossRefPubMed
37.
Fagiani E, Giardina G, Luzi L, Cesaroni M, Quarto M, Capra M, et al. RaLP, a new member of the Src homology and collagen family, regulates cell migration and tumor growth of metastatic melanomas. Cancer Res. 2007;67(7):3064–73.CrossRefPubMed
38.
Zhang X, Zhang H, Liao Z, Zhang J, Liang H, Wang W, et al. SHC4 promotes tumor proliferation and metastasis by activating STAT3 signaling in hepatocellular carcinoma. Cancer Cell Int. 2022;22(1):24.CrossRefPubMedPubMedCentral
39.
Yang H, Cai MY, Rong H, Ma LR, Xu YL. ZNF667-AS1, a positively regulating MEGF10, inhibits the progression of uveal melanoma by modulating cellular aggressiveness. J Biochem Mol Toxicol. 2021;35(5):e22732.CrossRefPubMed
40.
Mehta V, Suman P, Chander H. High levels of unfolded protein response component CHAC1 associates with cancer progression signatures in malignant breast cancer tissues. Clin Transl Oncol. 2022;24(12):2351–65.CrossRefPubMed
41.
Koetzier SC, van Langelaar J, Melief MJ, Wierenga-Wolf AF, Corsten CEA. Distinct Effector Programs of Brain-Homing CD8(+) T Cells in Multiple Sclerosis. Cells. 2022;11(10):1634.CrossRefPubMedPubMedCentral
Metadata
Title
TAP1, a potential immune-related prognosis biomarker with functional significance in uveal melanoma
Authors
Ru Zhu
Yu-Ting Chen
Bo-Wen Wang
Ya-Yan You
Xing-Hua Wang
Hua-Tao Xie
Fa-Gang Jiang
Ming-Chang Zhang
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2023
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-023-10527-9

Other articles of this Issue 1/2023

BMC Cancer 1/2023 Go to the issue

Correction

Correction: Associations between detectable circulating tumor DNA and tumor glucose uptake measured by 18F-FDG PET/CT in early-stage non-small cell lung cancer

Research

Factors associated with health-related quality of life in a cohort of cancer survivors in New Jersey

Research

Effect of chemotherapy alone or combined with immunotherapy for locally advanced or metastatic genitourinary small cell carcinoma: a real-world retrospective study

Research

Biochemical and pathophysiological improvements in rats with thioacetamide induced-hepatocellular carcinoma using aspirin plus vitamin C

Research

A nomogram based on platelet-to-lymphocyte ratio for predicting pathological complete response of breast cancer after neoadjuvant chemotherapy

Research

Clinicopathological features and prognosis of patients with HER2-low breast cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits